Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Kyle LaHucik

Senior Reporter

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals’ pain drug approval last month, is targeting up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

Pain biotech Lati­go eyes up to $150M raise fol­low­ing Ver­tex's land­mark FDA nod

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Ex­clu­sive: SV Health de­buts Parkin­son's biotech with back­ing from Ab­b­Vie and oth­ers

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects